Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

2.8K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
2.8K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

56
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
56
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

1.0K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
1.0K
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations01:26

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

173
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
173
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

290
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
290
Nursing Assessment of the Genitourinary System I: Health History01:21

Nursing Assessment of the Genitourinary System I: Health History

149
The genitourinary system is critical to maintaining fluid balance, waste elimination, and reproductive function. Nurses play a vital role in assessing this system, beginning with a thorough health history. This process involves gathering patient information, identifying risk factors, and recognizing symptoms of genitourinary disorders. Early detection is vital for timely interventions and management.1. Gathering Patient InformationA complete health history includes the patient’s personal,...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Lipid Peroxidation and Colorectal Cancer Risk: A Time-Varying Relationship.

International journal of cancer·2026
Same author

Baseline Inflammatory Cytokines Moderate Associations Between Intraoperative Oxidative Stress and Chronic Postsurgical Pain After Total Knee Arthroplasty: An Exploratory Study.

Journal of pain research·2026
Same author

Placental nicotinamide adenine dinucleotide modulates the timing of labor.

Science (New York, N.Y.)·2026
Same author

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Journal of the National Cancer Institute·2026
Same author

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

JNCI cancer spectrum·2026
Same author

Multi-ancestry transcriptome-wide association studies uncover insights into breast cancer genetics and biology.

Nature communications·2026

Related Experiment Video

Updated: Oct 22, 2025

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.2K

Urinary PGE-M in Men with Prostate Cancer.

Maeve Kiely1, Ginger L Milne2, Tsion Z Minas1

  • 1Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cancers
|August 27, 2021
PubMed
Summary
This summary is machine-generated.

Urinary prostaglandin E2 metabolite (PGE-M) levels were not linked to prostate cancer risk or aggressive disease. However, higher PGE-M correlated with increased mortality in African American men with prostate cancer who did not use aspirin.

Keywords:
aspirincyclooxygenasehealth disparityinflammationprostaglandin E metaboliteprostate cancer

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K

Related Experiment Videos

Last Updated: Oct 22, 2025

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.2K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K

Area of Science:

  • Oncology
  • Biochemistry
  • Epidemiology

Background:

  • Prostaglandin E2 (PGE2), a product of the COX inflammatory pathway, is implicated in cancer development and metastasis.
  • Aspirin is known to inhibit PGE2 synthesis.
  • Urinary PGE-M serves as a stable metabolite for assessing PGE2 levels.

Purpose of the Study:

  • To investigate the association between urinary PGE-M and lethal prostate cancer in African American and European American men.
  • To examine the relationship between PGE-M levels and prostate cancer aggressiveness and survival.

Main Methods:

  • A case-control study involving 977 prostate cancer cases and 1022 controls.
  • Urinary PGE-M measured via mass spectrometry.
  • Multivariable logistic and Cox regression models used to analyze associations with survival and disease, considering race and aspirin use.

Main Results:

  • No significant difference in urinary PGE-M levels between prostate cancer cases and controls.
  • PGE-M was not associated with aggressive prostate cancer or prostate cancer-specific survival.
  • Higher PGE-M was linked to increased all-cause mortality in African American cases not using aspirin (HR=2.04), but not in aspirin users.

Conclusions:

  • Urinary PGE-M is not a significant indicator for prostate cancer risk or aggressive disease.
  • Elevated PGE-M may be associated with higher all-cause mortality in African American men with prostate cancer who do not use aspirin.
  • Findings suggest a potential mortality-reducing benefit of aspirin for African American men with prostate cancer.